Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $137.70 | Total: $688.50 |
| 1 | 10 | $116.64 | Total: $1,166.40 |
| 1 | 25 | $98.82 | Total: $2,470.50 |
| 1 | 50 | $84.24 | Total: $4,212.00 |
| 1 | 100 | $72.90 | Total: $7,290.00 |
Overview
Ripisartan (UP-269-6) is a potent and specific angiotensin II receptor antagonist that inhibits angiotensin II-mediated sympathetic tachycardia responses.
Chemical Properties
| Molecular Formula | C23H22N8O |
| Molecular Weight | 426.47 |
| CAS Numbers | 148504-51-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(C=1C=2N(C(C)=NC1CCC)NC(=O)N2)C3=CC=C(C=C3)C4=C(C=CC=C4)C=5NN=NN5 |
Storage and Handling
0C Short Term, -20C Long Term
References
Cazes M, et al. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;284[1-2] 157-170.